RT Journal Article
SR Electronic
T1 Modulation of motor cortical excitability by continuous theta-burst stimulation in adults with autism spectrum disorder: The roles of <em>BDNF</em> and <em>APOE</em> polymorphisms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20083162
DO 10.1101/2020.05.11.20083162
A1 Ali Jannati
A1 Mary A. Ryan
A1 Gabrielle Block
A1 Fae B. Kayarian
A1 Lindsay M. Oberman
A1 Alexander Rotenberg
A1 Alvaro Pascual-Leone
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.11.20083162.abstract
AB Objective To assess the utility of the modulation of motor cortex (M1) excitability by continuous theta-burst stimulation (cTBS) as a physiologic biomarker for adults with autism spectrum disorder (ASD), and to evaluate the influences of brain-derived neurotrophic factor (BDNF) and apolipoprotein E (APOE) polymorphisms on cTBS aftereffects.Methods 44 neurotypical individuals (NT; age 21–65, 34 males) and 19 age-matched adults with high-functioning ASD (age 21–58, 17 males) underwent M1 cTBS. Cortico-motor reactivity was assessed before cTBS and thereafter every 5–10 minutes for 60 minutes (T5–T60).Results Logistic regressions found cTBS-induced change in amplitude of motor evoked potentials (∆MEP) at T15 was a significant predictor of ASD diagnosis (p=0.04). ∆MEP at T15 remained a significant predictor of diagnosis among BDNF Met+ subjects and APOE ε4− subjects (p’s &lt; 0.05) but not BDNF Met− subjects. ∆MEP at T30 was the best predictor of diagnosis among APOE ε4+ subjects (p = 0.08).Conclusions We confirm previous findings on the utility of cTBS measures of plasticity for adults with ASD, and we find the diagnostic utility of cTBS is modulated by BDNF and APOE SNPs.Significance It is important to control for BDNF and APOE polymorphisms when comparing TBS aftereffects in ASD and NT individuals.Competing Interest StatementA.P.-L. is a co-founder of Linus Health; serves on the scientific advisory boards for Starlab Neuroscience, Neuroelectrics, Cognito, and Magstim; and is listed as inventor on several issued and pending patents on real-time integration of TMS with EEG and MRI. A.R. is a founder and advisor for Neuromotion, serves on the medical advisory board or has consulted for Cavion, Epihunter, Gamify, NeuroRex, Roche, Otsuka, and is listed as inventor on a patent related to integration of TMS and EEG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Clinical TrialNCT02836405Funding StatementThis study was primarily funded by the National Institutes of Health (NIH R01 MH100186). A.P.-L. was further supported by the Sidney R. Baer Jr. Foundation, the NIH (R01 HD069776, R01 NS073601, R21 MH099196, R21 NS085491, R21 HD07616), and Harvard Catalyst | The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1 RR025758). A.J. was further supported by postdoctoral fellowships from the Natural Sciences and Engineering Research Council of Canada (NSERC 454617) and the Canadian Institutes of Health Research (CIHR 41791). L.O. was further supported by the Simons Foundation Autism Research Initiative (SFARI) and the Nancy Lurie Marks Family Foundation. A.R. was further supported by the NIH (R01 NS088583), The Boston Children’s Hospital Translational Research Program, Autism Speaks, Massachusetts Life Sciences, The Assimon Family, Brainsway, CRE Medical, Eisai, Neuroelectrics, Roche, Sage Therapeutics, and Takeda Medical. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Institutes of Health, or any of the other listed granting agencies.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated for this study are available on request to the corresponding author.